Chen Juin Ting, Dadheech Nidheesh, Tan Eddie Han Pin, Ng Natasha Hui Jin, Koh Mickey Boon Chai, Shapiro James, Teo Adrian Kee Keong
Stem Cells and Diabetes Laboratory, Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore.
Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Nat Med. 2025 Jun 27. doi: 10.1038/s41591-025-03767-8.
Diabetes has long-term, potentially severe implications for healthspan and lifespan and imposes an immense burden on global healthcare, the economy and society. Although a repertoire of medications is available to treat diabetes, these do not properly address the eventual lack of functional pancreatic beta cells that are needed to secrete insulin and maintain glucose homeostasis. Human islet cell transplantation from deceased donors is an established treatment for insulin-requiring type 1 diabetes, but demand outstrips supply. Substantial scientific and clinical progress has occurred in the last decade toward deriving pancreatic islet-like cells from human pluripotent stem cells, suggesting a potentially limitless solution to the supply issue and a new era in cell therapy for diabetes. Here, we critically review the scientific advances, the clinical trials and the various regulatory considerations that will need to be overcome for human stem cell-derived pancreatic islet-like cells to become the next cell therapy breakthrough for diabetes treatment.
糖尿病对健康寿命和寿命有着长期的、潜在的严重影响，并给全球医疗保健、经济和社会带来巨大负担。尽管有一系列药物可用于治疗糖尿病，但这些药物并不能妥善解决最终所需的功能性胰腺β细胞的缺乏问题，而这些细胞对于分泌胰岛素和维持葡萄糖稳态至关重要。来自已故供体的人胰岛细胞移植是治疗需要胰岛素的1型糖尿病的既定疗法，但需求超过了供应。在过去十年中，从人类多能干细胞中获取胰腺胰岛样细胞取得了重大的科学和临床进展，这为供应问题提供了一个潜在的无限解决方案，并开启了糖尿病细胞治疗的新时代。在此，我们批判性地回顾了科学进展、临床试验以及人类干细胞衍生的胰腺胰岛样细胞要成为糖尿病治疗的下一个细胞治疗突破所需要克服的各种监管考量。
